Volume 1, Issue 3

COPD: Inhaled Therapy Strategies

In this issue:

Chronic obstructive pulmonary disease (COPD) continues to be a leading cause of death in the world. COPD is also punctuated by periods of acute worsening of disease (exacerbations), which lead to worse prognosis and quality of life, as well as higher health care costs. Inhaled bronchodilator and corticosteroid therapy have been the mainstay of treatment for the prevention of exacerbations; however, the most appropriate combination of inhaled therapy to maximize benefit and reduce adverse effects has been less clear.  

In this issue Dr. Nadia Hansel from Johns Hopkins University School of Medicine reviews recent key publications that support the current GOLD recommendations for managing patients with symptomatic COPD and a history of exacerbations.  

Learning objectives:

  • Discuss the evidence for the preferred treatment strategy for patients with GOLD grade C and D COPD (history of ³ 2 exacerbations or ³1 exacerbation leading to hospitalization in the previous year).  
  • Recognize the benefit of ICS therapy in addition to LABA or LAMA therapy in preventing exacerbations. 
  • Identify the role of supplemental oxygen therapy in patients with moderate resting desaturation or exercise-induced desaturation. 


Nadia N. Hansel, MD, MPH
Nadia N. Hansel, MD, MPH

Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Program Directors:

Gregory B. Diette, MD

Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christine Smith, RN, MSN

Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
Baltimore, Maryland

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: May 18, 2018
Expiration date: May 17, 2020